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The effectiveness of percutaneous transluminal
angioplasty for the treatment of critical limb
ischemia: A 10-year experience
Toshifumi Kudo, MD, PhD, Fiona A. Chandra, and Samuel S. Ahn, MD, Los Angeles, Calif
Objective: To determine the efficacy, safety, and long-term results, including continued clinical improvement and limb
salvage, of percutaneous transluminal angioplasty (PTA) in patients with critical limb ischemia (CLI).
Methods: From August 1993 to March 2004, 138 limbs in 111 patients with CLI (rest pain in 62 [45%] and
ulcer/gangrene in 76 [55%]) were treated by PTA. In iliac lesions, stents were placed selectively for primary PTA failure:
residual stenosis (>30%) or pressure gradient (>5 mm Hg). Stent placement was limited in infrainguinal lesions. The
most distal affected arteries treated with angioplasty were the iliac artery in 45 limbs (33%; iliac group), the femoropop-
liteal artery in 41 limbs (30%; FP group), and tibial arteries in 52 limbs (37%; BK group). All analysis was performed
according to an intent-to-treat basis. Reporting standards of the Society for Vascular Surgery and the International
Society for Cardiovascular Surgery were followed to evaluate initial success, and late follow-up status was evaluated with
the Kaplan-Meier method. Patency was evaluated by using ultrasound scanning and ankle-brachial pressure index
measurement.
Results: There was one (0.9%) perioperative death. Twenty stents were placed selectively in 14 iliac arteries. Mean
follow-up was 14.7 months (range, 1-75 months). Overall, initial technical and clinical success rates were 96.4% and
92.8%, respectively. The cumulative primary, assisted primary, and secondary patency; continued clinical improvement;
and limb salvage rates  SE at 5 years were 31.4%  10.4%, 75.5%  5.7%, 79.6%  5.5%, 36.1%  10.0%, and 89.1% 
4.0%, respectively. In each subgroup, the primary, assisted primary, and secondary patency; continued clinical improve-
ment; and limb salvage rates at 3 years were 51.6%, 94.7%, 97.8%, 65.1%, and 95.0%, respectively, in the iliac group;
49.4%, 72.2%, 76.4%, 57.4%, and 92.7%, respectively, in the FP group; and 23.5%, 41.8%, 46.1%, 51.1%, and 77.3%,
respectively, in the BK group. Of the 12 predictable variables, hypertension, multiple segment lesions, more distal lesions,
and TransAtlantic Inter-Society Consensus classification type D were significant independent risk factors for the
outcomes (P < .05; univariate log-rank test and Cox regression multivariate analysis).
Conclusions: PTA is a feasible, safe, and effective procedure for the treatment of CLI. The high limb salvage rate is attributed
to the high assisted primary and secondary patency rates despite the low primary patency rate. Angioplasty can be the primary
choice for the treatment of CLI due to iliac and infrainguinal arterial occlusive disease. (J Vasc Surg 2005;41:423-35.)Critical limb ischemia (CLI) has been considered as a
primary indication for bypass surgery.1-3 Because of
compromised hemodynamic success or patency rates af-
ter percutaneous transluminal angioplasty (PTA) in pa-
tients with CLI, some investigators have suggested that
PTA in these patients should be confined to unusual
circumstances, such as high risk for surgery or no autog-
enous bypass material available.1-3 In recent years, with
continuing advances in imaging techniques, angioplasty
equipment, and endovascular expertise, the use of PTA
as a primary treatment for CLI has been increasing.4 The
lower morbidity and cost and results comparable to
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significant role of PTA for CLI.5
Moreover, an increasing number of multisegment
and more complicated arterial lesions are currently
treated by angioplasty in patients with CLI.4 Although
many reports have demonstrated the effectiveness of
PTA on CLI applied to each arterial segment, including
the iliac,6 femoropopliteal,7 and tibial arteries,8,9 not as
many reports4,10-14 have supported the general effective-
ness of angioplasty on patients with CLI, and this has yet
to be determined. Additionally, to our knowledge, few
data have been published regarding long-term results,
limited to 3 or 4 years, of PTA for CLI, which includes all
anatomic lesions in the lower extremity.11,12 The pur-
pose of this study was to evaluate the total effectiveness
of PTA in patients with CLI and the short- and long-
term outcomes in terms of feasibility, safety, patency,
clinical improvement, and limb salvage.
METHODS
Patient population. From August 1993 to March
2004, 138 limbs in 111 patients with CLI were treated
423
JOURNAL OF VASCULAR SURGERY
March 2005424 Kudo et alby PTA at the University of California, Los Angeles, by a
single vascular surgeon. All patients were primary cases.
Patients who underwent a concomitant aortoiliac or
infrainguinal open bypass operation on the same day or
within 30 days before PTA were excluded from this
study. Patients who were treated with a covered stent
(three limbs) were not included. During the same pe-
riod, 128 limbs underwent open operations (76 limbs
with CLI and 48 limbs with claudication) without at-
tempts at angioplasty or in combination with angio-
plasty. Sixty-four limbs underwent angioplasty with or
without stent placement for claudication, and nine limbs
underwent combined surgery (endovascular plus open
surgery). Above-ankle amputations were performed in
two patients without attempts at either PTA or bypass
surgery.
All patients with CLI were treated with the same
protocol. In patients with multiple lesions, ie, severe
proximal (iliac, femoropopliteal, or both) lesions and
mild or moderate distal (femoropopliteal, tibial, or both)
lesions, proximal lesions were treated first without distal
angioplasty; patients whose main lesions were distal
(femoropopliteal, tibial, or both) arteries were treated
with distal angioplasty with or without concomitant
proximal angioplasty. In iliac lesions, stents were placed
selectively for primary PTA failure, including residual
stenosis (30%), pressure gradient (5 mm Hg), or
both; stent placement was limited to patients with fem-
oropopliteal occlusive lesions that did not respond to
balloon dilation because of elastic recoil, arterial dissec-
tion, or both. No stent was placed in tibial lesions.
Before-and-after pressures were routinely measured with
papaverine injection in patients with iliac lesions and
only when the patient had an angiographic problem, ie,
residual stenosis, in patients with infrainguinal lesions.
The criteria for open bypass surgery as the primary
treatment for CLI were (1) bilateral common iliac artery
occlusion, (2) unilateral external iliac occlusion, or (3)
long (10-cm) infrainguinal occlusion starting from the
orifice of the superficial femoral artery (SFA). Long
lesions with an open segment of proximal SFA were
treated with PTA.
All patients had evidence of chronic CLI, defined as rest
pain or ulcer/gangrene, and were included in a retrospec-
tive cohort study. Preoperative, intraoperative, and follow-
up information was available for all patients; this informa-
tion was obtained via office and hospital chart reviews and
dictated operative records. The study protocol was ap-
proved by the local institutional review board.
PTA and stent technique. Angioplasty was per-
formed in the operating room for all patients through an
ipsilateral or contralateral femoral approach by using
various sizes of introducer sheaths ranging from 5F to 9F
(5F sheaths in 81 limbs [59%], 6F in 32 [23%], 7F in 23
[17%], 8F in 1 [0.7%], and 9F in 1 [0.7%]). Before
intervention, arteriography was performed to quantify
the extent of the disease in the operating room. Heparin
sodium (100 IU/kg) was administered systemically. Intibial lesions, catheterization was made with “road map-
ping” of the arteries. Occlusions and stenoses were
passed with a 0.014- to 0.035-inch guidewire. PTA was
performed with standard angioplasty balloons (2-10 cm
in length; 2-10 mm in diameter) selected to match the
length of the lesion and the diameter of the artery.
Pressure was 8 to 16 atm. Balloon inflation was repeated
routinely two to four times at the same segment. If the
primary angioplasty resulted in residual stenosis, angio-
plasty was repeated with a balloon 1 mm larger than the
previous one. This protocol was applied prospectively to
all patients. Patients were given aspirin before and after
the procedure and were continued on aspirin thereafter.
During the period of this study, the technique of PTA
and stent placement did not change significantly. The
indication of PTA for tibial lesions has been more aggres-
sive recently, ie, for more distal or diffuse lesions and
total occlusions.
Hemodynamic and radiologic evaluation. Ankle-
Table I. Characteristics of the subjects treated with
angioplasty for critical limb ischemia (111 cases; mean
age  SD, 70.9  11.5 years)
Variable n %
Male 64 58%
Female 47 42%
Coronary artery disease 67 58%
Diabetes mellitus 67 58%
Hypertension 64 57%
Smoking 44 40%
Hyperlipidemia 37 33%
Chronic renal failure with hemodialysis 22 20%
Cerebrovascular disease 14 13%
Chronic obstructive lung disease 6 5%
Table II. Characteristics of the limbs treated with
angioplasty for critical limb ischemia: 138 limbs
Variable n %
Indication for PTA
Ischemic rest pain 62 45%
Ulcer/gangrene 76 55%
No. of segments treated*
1 76 55%
2 60 43%
3 2 2%
The most distal artery treated
Iliac artery (iliac group) 45 33%
Femoropopliteal artery (FP group) 41 30%
Tibial arteries (BK group) 52 37%
TASC classification for the lower limb
Type A 0
Type B 13 9%
Type C 74 54%
Type D 51 37%
PTA, Percutaneous transluminal angioplasty; TASC, TransAtlantic Inter-
Society Consensus.
*Iliac, femoropopliteal, and/or tibial segments.brachial pressure index (ABI) measurements and duplex
16.4
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waveforms were also evaluated in limbs with falsely in-
creased ankle pressures caused by severe arterial calcifica-
tion. Patients were usually seen within 2 weeks after the
Fig 1. Kaplan-Meier life-table analysis of outcomes afte
line, Portion of plot where the SE is greater than 10%.
Table III. Outcomes of the limbs treated with angioplast
life-table analysis)
Group n
Time
interval
(mo)
Primary
patency
Assisted p
paten
All patients 138 60 31.4%  10.4% 75.5% 
Iliac group 45 36 51.6%  11.0% 94.7% 
FP group 41 36 49.4%  11.9% 72.2% 
BK group 52 36 23.5%  10.7% 41.8% procedure. Postoperative follow-up (clinical examination,ABI measurements, and serial duplex ultrasound scanning)
was conducted every 3 months during the first postopera-
tive year and every 6 months thereafter. Indications for
repeat intervention included recurrent symptoms accompa-
ioplasty for critical limb ischemia in 138 limbs. Dashed
critical limb ischemia in each subgroup (Kaplan-Meier
ry Secondary
patency
Continued clinical
improvement
Limb
salvage
79.6%  5.5% 36.1%  10.0% 89.1%  4.0%
97.8%  2.1% 65.1%  10.1% 95.0%  4.8%
76.4%  9.1% 57.4%  13.5% 92.7%  4.0%
% 46.1%  17.6% 51.1%  12.5% 77.3%  11.5%r angy for
rima
cy
5.7%
3.6%
9.8%nied by a less than 0.10 increase in ABI or recurrent stenosis
JOURNAL OF VASCULAR SURGERY
March 2005426 Kudo et algreater than 60% by duplex scan (a threefold difference of
the velocity across the lesion is estimated as a 60%-80%
stenosis by our institute’s vascular laboratory). Patients
with insufficient vascular laboratory records were consid-
ered lost to follow-up in patency analysis.
Data analysis. The occlusive lesions in the lower ex-
tremity were classified by angiographic findings according
to TransAtlantic Inter-Society Consensus (TASC).15 The
procedure on the most distal arterial segment (iliac, femo-
ropopliteal, or tibial) of one limb in each patient was
evaluated. Demographic information, risk factors, and all
independent variables were statistically analyzed and corre-
lated with outcome. Success of PTA was defined anatomi-
cally, hemodynamically, and clinically according to the
Society for Vascular Surgery and the International Society
Table IV. Variables tested for outcomes after angioplasty
Variable No.
Pr
Failure rate p
person-mon
Gender
Male 80 3.234
Female 58 4.141
Age
 70 68 3.647
70 or  70 70 3.499
Smoking
Yes 56 3.491
No 82 3.641
Coronary artery disease
Yes 88 3.522
No 50 3.688
Hypertension
Yes 88 4.955
No 50 2.034
Diabetes mellitus
Yes 84 4.229
No 54 2.677
Hyperlipidemia
Yes 51 2.767
No 87 4.133
Chronic renal failure with hemodialysis
Yes 27 2.869
No 111 3.755
Indication for PTA
Rest pain 62 3.333
Ulcer/gangrene 76 3.834
No. of segments treated*
1 76 2.486
2/3 62 7.095
The most distal artery treated
Iliac group 45 2.054
FP group 41 3.723
BK group 52 7.287
TASC classification
B 13 0.909
C 74 2.789
D 51 5.852
Kaplan-Meier, log-rank test.
PTA, Percutaneous transluminal angioplasty; TASC, TransAtlantic Inter-So
*Iliac, femoropopliteal, and/or tibial segments.for Cardiovascular Surgery reporting standards16,17: (1)PTAwas deemed technically successful if there was less than
30% residual stenosis and, in iliac lesions, the brachiofemo-
ral pressure gradient was less than 5 mm Hg; (2) PTA was
considered as a clinical success/improvement if the symp-
toms improved by at least one category together with an
increase in ABI of more than 0.10 (this constitutes primary
clinical success instead of continued or corrected clinical
success after successful reintervention); (3) patency was
determined by duplex scans, ABI measurements, or both;
(4) all revisions performed on the basis of the criteria
described previously or occlusion at any lesion on the same
limb were considered primary PTA failures; and (5) all
analysis was performed on an intent-to-treat basis, includ-
ing initial technical failures.
Statistical analysis. The Kaplan-Meier method (KM)
tients with critical limb ischemia: 138 limbs.
y patency Assisted primary patency
Rate
ratio P
Failure rate per 100
person-months
Rate
ratio P
0.78 .51 1.1 0.99 .83
1 1.106 1
1 .62 1.14 1 .45
0.96 1.05 0.92
0.96 .68 0.813 0.64 .24
1 1.278 1
0.96 .84 1.248 1.5 .44
1 0.847 1
2.44 .024 0.846 1 .53
1 1.3 1.5
1.56 .14 1.275 1.6 .27
1 0.817 1
0.67 .27 0.806 0.63 .32
1 1.285 1
0.76 .62 1.19 1.09 .90
1 1.087 1
0.87 .24 0.848 0.58 .40
1 1.415 1
1 .0083 0.571 1 .028
2.85 0.85 4.7
0.28 .0077 0.117 0.03 .0026
0.51 1.59 0.48
1 3.309 1
1 .0158 0 .0015
3.1 0.466 N/A
6.4 2.908
Consensus.in pa
imar
er 100
ths
cietywas used to determine the outcome at sequential intervals.
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univariate log-rank test and multivariate Cox regression
model. Statistical significance was defined as a P value
.05.
RESULTS
Demographic information. The clinical characteris-
tics of 111 patients are summarized in Tables I and II.
There were 64 men (58%) and 47 (42%) women, with a
mean age of 7.09 years (range, 45-98 years). Twenty-
seven patients (24%) were older than 80 years during the
time of the initial procedure. Fourteen limbs (10%) were
noted to have falsely increased ankle pressure (250 mm
Hg). In the remaining limbs, the mean ABI was 0.4
(range, 0.19-0.89) before intervention. Indications for
PTA were ischemic rest pain in 62 limbs (45%) and
ulcer/gangrene in 76 limbs (55%). The most distal af-
fected arteries treated with angioplasty were the com-
Table IV. Continued.
Secondary patency Continued cli
Failure rate per 100
person-months
Rate
ratio P
Failure rate per 1
person-months
1.087 1.4 .73 2.071
0.793 1 2.411
0.891 1 .77 1.599
1.049 1.2 3.201
0.806 0.8 .45 2.247
1.041 1 2.19
1.012 1.2 .70 2.172
0.847 1 2.28
1.033 1.2 .84 2.346
0.846 1 2.011
1.133 1.8 .24 2.309
0.647 1 2.024
0.64 0.6 .26 1.463
1.141 1 2.627
0.76 0.8 .54 3.731
0.99 1 1.93
0.848 0.8 .86 1.386
1.09 1 3.385
0.475 1 .023 1.726
2.381 5 3.419
0.116 0.04 .0104 1.527
1.304 0.5 2.49
2.878 1 0.83
0 .0098 0.645
0.463 N/A 1.661
2.263 3.958mon and/or external iliac artery in 45 limbs (33%; iliacgroup), the femoral (common, superficial, and/or deep
femoral) and/or popliteal artery in 41 (30%; FP group),
and the tibial arteries in 52 (37%; BK group). In the iliac
group, 14 limbs (28%) underwent the selective place-
ment of 1 to 3 stents (20 stents in total). In the FP group,
16 limbs (39%) underwent concomitant iliac PTA,
whereas PTA was performed in the femoropopliteal seg-
ments alone on 25 limbs (61%). In the BK group,
concomitant proximal angioplasty was performed on 42
limbs (81%)—in the SFA on 12 (23%), in the popliteal
artery on 6 (12%), and in the femoropopliteal segment
on 24 (46%)—whereas only tibial arteries were treated
with PTA on 10 (19%). Subintimal angioplasty was
performed in most of the totally occluded lesions treated
(1 iliac, 8 superficial femoral, 12 popliteal, and 6 tibial
arteries). Only two limbs (2.4%) underwent stent place-
ment in the femoral and/or popliteal arteries.
Initial success and early complications. The average
improvement Limb salvage
Rate
ratio P
Failure rate per 100
person-months
Rate
ratio P
0.9 .29 0.435 0.9 .85
1 0.469 1
1 .27 0.505 1 .37
2 0.369 0.7
1.02 .93 0.606 1.6 .72
1 0.373 1
0.95 .84 0.377 0.6 .59
1 0.592 1
1.2 .84 0.342 0.6 .30
1 0.602 1
1.1 .61 0.444 0.96 .81
1 0.461 1
0.6 .14 0.288 0.5 .37
1 0.536 1
1.9 .18 0.612 1.5 .81
1 0.418 1
0.4 .064 0.281 0.4 .31
1 0.641 1
1 .21 0.215 1 .083
1.9 0.873 4
0.5 .62 0.117 0.1 .20
0.8 0.465 0.5
1 1.002 1
1 .053 0 .0034
2.6 0.085 N/A
6.1 1.203nical
00hospital stay was 3.2 days (range, 0-30 days). In 138
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(96.4%), and initial clinical success was obtained in 128
limbs (92.8%). Procedural mortality, defined as death
within 30 days after the procedures, was 1 (0.9%) in 111.
Five limbs (3.6%) underwent above-ankle amputation
within 30 days. Groin and/or flank hematoma that
required evacuation occurred in three patients (2.2%).
There was no other major complication.
Long-term success. The mean follow-up was 14.7
months (range, 1-75 months). Eighteen patients (13%)
were lost to follow-up. Primary PTAs were followed by
subsequent open bypass surgery in 13 limbs (9.4%; 5
popliteal, 6 tibial, and 2 pedal bypass operations) for the
purpose of limb salvage: 6 limbs in the iliac group, 4
limbs in the FP group, and 3 limbs in the BK group. A
total of nine limbs (6.5%), including the five within 30
days after PTA, underwent above-ankle amputation
(eight below the knee and one above the knee). Of these
nine limbs, no distal bypass surgery was attempted be-
cause of unreconstructable distal vessels and advanced
gangrene and/or infection, except for one that under-
went subsequent external iliac-to-popliteal bypass in the
iliac group. Six of the patients with amputated limbs had
diabetes, and the indications for the initial PTA were
gangrene in six limbs and rest pain in three limbs.
Over all, the cumulative primary patency, assisted primary
patency, secondary patency, continued clinical improvement,
and limb salvage rates  SE at 5 years were 31.4%  10.4%,
75.5% 5.7%, 79.6% 5.5%, 36.1% 10.0%, and 89.1%
4.0%, respectively (Fig 1 and Table III). The results for the
iliac, FP, and BK groups at 36 months are presented in Table
III.
Univariate analysis of risk factors. Of the 12 pre-
dictable variables studied in 138 limbs, 4 were significant
(Table IV). Primary patency was significantly decreased for
hypertensive patients (KM; log-rank test; P  .027; Fig 2).
Both multiple-segment lesions and more distal lesions sig-
nificantly decreased primary, assisted primary, and second-
ary patency rates (KM; log-rank test; P  .05; Figs 3 and 4).
Patients with TASC type D had significantly decreased
primary, assisted primary, secondary patency, and limb
salvage rates (KM; log-rank test; P  .05; Fig 5). There was
a trend that ulcer/gangrene (P  .064) and TASC type D
(P .053) decreased continued clinical improvement (Ta-
ble IV).
Multivariate analysis of risk factors. Multiple re-
gression analysis revealed that hypertension, the number of
segments treated, the most distal segments treated, and
TASC classification were significant independent risk fac-
tors (P  .05; Table V).
DISCUSSION
The role of PTA for CLI is still controversial. How-
ever, the clinical advantages of PTA are well established
for the high-risk, elderly, and vascularly compromised
patient: there is no need for general or spinal anesthesia,
there are no or fewer surgical wounds, the hospital stay is
shorter, and complication and mortality rates arelow.13,18 The angiographic evaluation in the operating
room on the same day of endovascular procedures re-
duces both patient stress and the amount of contrast
administered: these are particularly relevant in patients
with cardiovascular diseases or nephropathy.19 For all
these reasons, we have been considering PTA as a first-
line procedure in patients with CLI whenever possible
and have not limited the indication for PTA to patients
who cannot undergo an operation. Bypass surgery has
been considered a second-line procedure after PTA fail-
ure except for patients with the criteria mentioned pre-
viously. We considered it clinically important to review
the outcome of PTA for all patients with CLI because it
may dictate the best treatment for those subjects.
This study revealed a high technical success rate (96%),
a high initial clinical success rate (93%), and a low compli-
cation rate (2%). These results are in agreement with other
reports.4,8,12 The overall procedure-related serious compli-
cation rate within 30 days after angioplasty for CLI, includ-
ing death, acute renal failure, and limb loss, was less than 1%
in this series.
However, the primary patency rate was low in this
study: 31.4% at 5 years. Compared with patients with
intermittent claudication, patients with CLI seem to have
much higher re-stenosis rates.10 This result might reflect
the characteristic factors of our CLI population. In this
study, 58% were diabetic, 24% were older than 80 years of
age, 20% had chronic renal failure and hemodialysis, and all
but one who underwent major amputations had unrecon-
structable distal vessels and advanced gangrene, infection,
or both. Inclusion of these patients probably had a negative
Fig 2. Kaplan-Meier life-table analysis (log-rank test) of primary
patency rates. Hypertensive [HT ()] patients had significantly
decreased primary patency rates compared with nonhypertensive
[HT ()] patients. Dashed line, Portion of plot where the SE is
greater than 10%.effect on the results of PTA.
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not considered as a primary treatment modality for CLI.3
However, clinical improvement and avoidance of major
amputation are more crucial elements when assessing the
efficacy of any therapeutic approach for CLI. In our expe-
rience, the clinical recurrence rate was not high; primary
continued clinical improvement was maintained in 74% of
limbs at 1 year and in 58% at 3 years. This result is higher
than the primary patency rate described in previous re-
ports.8 Additionally, the above-the-ankle amputation rates
in our series were low. In patients with unreconstructed
CLI, a 54% limb salvage rate at 1 year has been reported.20
Fig 3. Kaplan-Meier life-table analysis in patients with
rates.B, Assisted primary patency rates.C, Secondary pat
than 10%.Our short-term limb salvage rate (92% at 1 year) was muchhigher than that, which was in agreement with previous
reports: 88% at 12 months4 and 80% at 18 months.8 Our
long-term limb salvage rate was still high: 89% at 6 years. As
the site of PTA moves more distally in the arterial tree, the
benefits have been considered less clear.3 However, strati-
fied analysis in our study revealed that each subgroup
showed a good limb salvage rate in our series. These results
support the argument that PTA is a rational treatment
option for all CLI.
The reason for better primary continued clinical improve-
ment and limb salvage rates compared with primary patency
rates might be explained as follows. (1) Extra perfusion is
and two or three segments treated. A, Primary patency
rates.Dashed line, Portion of plot where the SE is greaterone
encynecessary to heal the tissue loss, but once it heals, the skin
n 10%
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re-occluded;11 and (2) slow re-stenosis of the treated artery
allows time to formnew collateral circulation.Whenno pain is
present or tissue healing has occurred in CLI patients, a
possible delayed closure of the recanalized vessel may not
always be clinically relevant.13 This is similar to the limb that
remained intact after the original bypass thrombosed.21
Some shortcomings of this study, such as the bypass
Fig 4. Kaplan-Meier life-table analysis in the iliac, patients
common or external iliac artery; FP, patients with the m
(common, superficial, or deep femoral) or popliteal artery; a
PTA were the tibial arteries groups.A, Primary patency rate
Dashed line, Portion of the plot where the SE is greater thacases and those lost to follow-up, might have partiallycontributed to the high limb salvage rate. Thus, we re-
evaluated the limb salvage rate by excluding the 13 bypass
cases but still found a similar limb salvage rate (87.3% 
4.8%) at 5 years. When we excluded the patients who were
lost to follow-up (18 limbs), the primary, assisted primary,
secondary, continued clinical improvement, and limb sal-
vage rates  SE at 5 years were 29.9%  10.1%, 75.7% 
6.0%, 78.8%  5.7%, 34.4%  9.6%, and 88.2%  4.2%,
the most distal affected arteries treated with PTA were the
istal affected arteries treated with PTA were the femoral
, patients with themost distal affected arteries treatedwith
Assisted primary patency rates.C, Secondary patency rates.
. PTA, Percutaneous transluminal angioplasty.with
ost d
nd BK
s.B,respectively. These results are similar to our previously
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and those lost to follow-up. Thus, we believe that repeat
angioplasty plays a significant role, because our assisted
primary (75.5% at 5 years) and secondary (79.6% at 5 years)
patency rates were excellent and similar to our limb salvage
rate. The mean follow-up (14.7 months) was short, be-
cause (1) 40.6% of limbs (56/138) were treated in the last
2 years during the study period; (2) the mortality rate was
high (56% at 5 years) in the population; and (3) 18 limbs
Fig 5. Kaplan-Meier life-table analysis in TransAtlant
patency rates.B,Assisted primary patency rates.C, Secon
of the plot where the SE is greater than 10%.(13%) were lost to follow-up.Although PTA seems to allow satisfactory continued
clinical improvement and limb salvage, its effectiveness as
the primary procedure in patients with CLI in comparison
with conventional bypass surgery has not been determined.
One prospective study with severe lower limb ischemia
reported that PTA and bypass surgery achieved the same
limb salvage rate of 76% at 1 year.22 Another recent pro-
spective study demonstrated that angioplasty can be used in
the management of CLI without compromising limb sal-
er-Society Consensus types B, C, and D. A, Primary
atency rates.D, Limb salvage rates.Dashed line, Portionic Int
dary pvage, patient survival, and subsequent vascular interven-
inal a
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the 5-year limb salvage rate was 89%, which is comparable
to those reported previously in the series of patients with
bypass surgery: a 5-year rate of 70% to 80%.24 Additionally,
several previous studies have shown that failure of angio-
plasty did not preclude the possibility of performing subse-
quent bypass grafting.4 In a previous study of tibial PTA in
diabetic patients with ischemic foot ulcers, clinical recur-
rence was well managed by a second PTA.11 These studies
also support that PTA can be the first-line treatment for
CLI patients even though they are not poor surgical candi-
dates. Finally, CLI is a manifestation of a diffuse, severe
form of arteriosclerosis, which is reflected in the high death
rates of previous reports: 20% to 27% at 1 year,10,25 31.6%
at 2 years,26 and more than 60% at 5 years.27 The 5-year
mortality rate was 56% in this study. These data suggest that
a clinical benefit (symptomatic improvement and limb sal-
vage) and defect (complication) from a treatment proce-
dure might be more essential than long-term patency for
patients with severe CLI symptoms, including ulcers and
gangrene, as well as rest pain.
We studied the effects of 12 predictable variables on
patency, continued clinical improvement, and limb sal-
vage. The univariate log-rank test and multivariate anal-
ysis revealed that four independent factors might affect
PTA outcome: hypertension, the number of segments
treated, the most distal segments treated, and TASC
classification. All factors likely reflected a severe systemic
and peripheral extent of arteriosclerosis, which would be
associated with poor outcome. However, it is not appro-
priate to conclude that PTA is not worthwhile for this
subgroup. Even though (1) the BK group had the most
predisposing risk factors (approximately 60% were dia-
betic, almost a third had chronic renal failure and hemo-
dialysis, and almost a third were older than 80 years of
age) and (2) all patients with amputations in the BK
group had unreconstructable distal vessels, they still had
a reasonable limb salvage rate, and endovascular proce-
Table V. Multivariate analysis: risk factors for adverse out
Variable
Hazard
ratio
Primary patency
Hypertension 2.673
The most distal artery treated 0.387
TASC D vs TASC B  C 2.542
Assisted primary patency
The most distal artery treated 0.139
TASC D vs TASC B  C 4.84
Secondary patency
The most distal artery treated 0.087
TASC D vs TASC B  C 4.596
Continued clinical improvement
Age (per year) 1.026
Indication for PTA 0.493
TASC D vs TASC B  C 2.26
TASC, TransAtlantic Inter-Society Consensus; PTA, percutaneous translumdures might be the only alternative to amputation.Judging the outcome of PTA as successful requires
objective and uniform criteria.17 We believe that the com-
bination of clinical examination and suitable noninvasive
diagnostic modalities, such as duplex ultrasonography,
might offer better follow-up evaluation after angioplasty. It
might also be useful for detection of re-stenosis and could
contribute to better assisted primary and secondary patency
rates.
In conclusion, PTA is a feasible, safe, and effective
procedure for the treatment of CLI. Initial technical and
clinical success rates were high, and procedural mortality
and complication rates were low. In long-term results,
our data demonstrated a 76% assisted primary rate, an
80% secondary patency rate, and an 89% limb salvage rate
at 5 years: the high limb salvage rate was attributed to the
high assisted primary and secondary patency rates despite
the low primary patency rate. Because the purpose of
treatment in this population is limb salvage and symptom
relief (rather than long-term primary patency), PTA can
be the primary choice for the management of CLI. Our
risk factor analysis indicated that hypertension, multiple
segment lesions, more distal lesions, and TASC type D
were significant independent predictors of worse long-
term results.
We acknowledge Jeffrey A. Gornbein, PhD, and Re-
becca Radbod, MPH, Statistical/Biomathematical Con-
sulting Clinic, Department of Biomathematics, UCLA, for
their statistical expertise and critical comments.
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Dr Timothy Liem (Portland, Ore). I would like to congrat-
ulate Drs Chandra, Kudo, and Ahn for their large series of patients,
which is especially notable since all the patients were treated by a
single vascular surgeon over a 10½-year period. I would also like to
thank the authors for timely submission of their manuscript.
The authors have demonstrated that in a select group of
patients with limb-threatening ischemia, percutaneous angioplasty
is a reasonable first option. I would agree with their practice of
offering percutaneous interventions not only to poor-surgical-risk
but also acceptable-surgical-risk patients. Ms Chandra has shown
us today that just as in open bypass surgery, the limb salvage rates
can be very acceptable, in the range of 77% to 89%, even when the
primary patency is significantly lower. In addition, the literature
has shown that patients with limb-threatening ischemia in general
have a fairly poor overall rate of survival, in the range of 50% at 3 or
5 years. As the authors stated, long-term primary patency may not
be as crucial in patients with such a limited life expectancy. My first
question relates to this: what was their 3- or 5-year survival in this
series of patients?
I also have a word of caution regarding one conclusion from
their manuscript stating that percutaneous angioplasty was feasible
in most patients with limb-threatening ischemia. I am not sure thatThe patients in this series were a fairly select group. Those
patients who had occlusions longer than 10 cm below the groin
and those who subsequently underwent open bypass within 30
days after percutaneous angioplasty were excluded. Many, if not
most, patients who present with limb-threatening ischemia will
have longer than 10 cm of arterial occlusion. Therefore, percuta-
neous angioplasty should certainly be in the armamentarium of a
vascular surgeon sometimes to be used as a sole treatment modality
in patients with shorter segment stenosis or occlusion. However,
my guess is that we will still use it more commonly in conjunction
with open surgical bypass for patients with critical limb ischemia.
I have a few more questions for the authors. They used stents
only selectively in the iliac arteries and not at all in the infrainguinal
arteries. Do the authors foresee a greater role for stents, primarily
primary stenting, in the future?
Second, what role is there for subintimal angioplasty, with or
without stenting?
Third, the authors used heparin around the time of the pro-
cedure and aspirin afterward. Are the authors using any other
medications, such as clopidogrel, before or after the angioplasty?
Finally, I have an additional question. There was a noted
decreased clinical improvement rate when compared with the limb
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ABI to still be significantly improved over that long-term period?
Again, I’d like to thank the authors for their presentation and
manuscript.
Dr Ahn. Thank you very much for those questions and your
thoughtful analysis. Ms Chandra is perfectly capable of answering
them, but I thought you might want to hear from the responsible
surgeon directly. Also, I might add that Ms Chandra is actually an
undergraduate student at UCLA. As you can see, she did a fine job
on presenting a very complicated medical problem.
In answer to the questions, the 3- and 5-year survival rates in
this series were 64% and 44%. As far as your comments about
excluding patients from the series and its being highly selective, I
think you said that we excluded patients after PTA, and that is an
inaccurate comment. We excluded patients who had open surgery
before any PTA, and those were the 58 patients who wementioned
were excluded. Those 58 patients were the ones who had an open
procedure either with or without PTA subsequently, and therefore
those were excluded so as not to contaminate the pure PTAs. Any
patients who had PTA or open surgery or stents after my initial
PTA were part of the study group, which numbered 111 in total.
Thus, you can see I excluded about a third of the patients (58 vs
111). Thatmeans two thirds of the patients had primary PTA as the
indication for the procedure. I must also say that earlier in the series
I was more inclined to do open surgery than PTA. In the past year
or two, I probably do a primary open procedure in only 10% to 20%
of the patients that I see with limb-threatening ischemia.
You asked some questions about the role of primary stenting
in the future. I think there is probably an increased role of primary
stenting in the external iliacs, and also I think there is an increased
role of cover stent grafts, ie, the Viabahn grafts, among others, in
the SFA and especially in patients who have long total occlusions.
There are very few long total occlusions that I cannot treat with
subintimal dissection plus or minus a cover stent graft.
Do I use any other medications now? Yes. Early in the series it
was only aspirin. In the past at least 1 year, I have added Plavix
routinely to these patients after surgery. Oh, by the way, when they
come back for reintervention, I keep them on the Plavix indefi-
nitely. I do not stop the Plavix at all.
Regarding the decreased clinical success rate, if you go back to
the original reporting standards article, the strict definition of
clinical success is primary clinical success. There is no word or
verbiage in that document to account for secondary or continued
clinical success. Thus, the clinical success rate follows the curves of
the primary patency and not the assisted primary patency, second-
ary patency, or limb salvage rates.
Dr Ronald Dalman (Stanford, Calif). I have a question, Sam.
On this cohort you get a 93% limb salvage for femoropopliteal
interventions at a 5-year mean follow-up and 77% for below-knee
interventions, and that just seems extraordinarily good compared
with open surgery, so part of the issue is, I guess, that we do not
know what the survival is, so maybe a lot of patients are dying early
at various times, and then the other point that Tim brought up was
that part of the patients, if they require bypass surgery within 30
days of the procedure, they are falling out too.
Dr Ahn. No, no, that is not true.
Dr Dalman. Help me understand. . .
Dr Ahn. If they required bypass surgery within 30 days or any
time after the PTA, that counted as a failure.
Dr Dalman.Okay, so do you have any comment about a 77%
limb salvage rate for below-knee catheter-based intervention at
5-year follow-up? Or is that just what it is?
Dr Ahn. I think that there are several explanations for that.
Number one is what you pointed out and Tim pointed out. It could
be a factor of the survival. Those patients with below-knee infraingui-
nal disease tend to be your diabetic chronic renal failure patients who
do not livemore than 2 to 4 years, and theymay drop out and die, but
they die with their limbs intact. The other is that the gangrene and
tissue loss only needs to heal, and once they heal, it probably doesn’t
matter whether your angioplasty site goes down or not because ittakes a lot more to heal an ulcer and gangrene than to maintain a
healed gangrene. Also, during that time after angioplasty, if they do
re-stenose, theymay have time to developmore collaterals during that
gradual re-stenosis. And then finally, I think there is a factor of good
surveillance, and I know several members here in this audience have
talked about the importance of surveillance. Our primary assisted
patency and our secondary patency are almost as good as our limb
salvage, and that is because of good surveillance. Our primary paten-
cies are awful, but we follow up our patients carefully, we intervene
when there is still a failing rather than a failed angioplasty site, and we
intervene and get a really good primary assisted patency and a really
good secondary patency, and that is reflected in our more favorable
limb salvage.
Dr James Watson (Seattle, Wash). I also would like to
congratulate Ms Chandra on an excellent presentation. I was
struck by your 25% primary patency of iliac interventions at 5 years.
That seems low to me. It is unclear what percentage of those were
just angioplasties and what percentage were stents. Has that
changed your practice, because most of the time now I don’t
perform bare iliac angioplasty without stent placement. Twenty-
five percent seems low. Has that changed your practice at all?
Dr Ahn. Yes. I think that low primary patency is reflected by
my aversion to use stents and also partly that these angioplasties do
need reintervention frequently, and I think our data point that out,
but as you can see, our secondary and primary assisted patencies
were superb. Again, it points back to the need for good surveil-
lance. I am more inclined now to use a primary stent for external
iliacs, as well as for re-stenosis, and hopefully my results 10 years
from now will reflect some improvement.
Dr George Andros (Los Angeles, Calif). First of all, you are on
a very slippery slope when you give us limb-threatening ischemia.
That is probably one of the most difficult subjects we deal with now,
and for myself I take the hard line. I think you have to give us really
good data. I want ankle pressures. I want toe pressures. I want to
know what the lesions looked like, and you just can’t say “this is
limb-threatening ischemia” and not characterize it to a fare-thee-well,
so I think that is the first problem you have with this. I really want to
know why these people, you think, are so ischemic.
My second question is, does this paper adhere to Andros’ first
two principles of endovascular therapy, the first being “the less you
need it, the better it works”? So, are these people really as bad as
you say? The second one is “get them healed.” Now you said you
just get them healed, and once they are healed, if the revascular-
ization goes down they will stay healed, and that is entirely contrary
to the data in the literature and my own personal experience.
Fifty-eight percent of your patients were diabetics. Were these
people really having rest pain? Diabetics don’t get rest pain; they
get neuropathy. So I would like to have that better characterized.
Do you measure hemodynamic success intraprocedurally? For
example, do you routinely do not just the cosmetic, the appearance
of the lesion, but do you do before-and-after pressures with and
without papaverine? I ask that because we are now locked in a
mortal battle with the interventional radiologists and the cardiol-
ogists, and if we are going to play the game according to their rules
(which is do the procedure, look at the result, and send a bill), we
have to do better than that because if we are going to play the game
the way they play it, we are going to lose, but if we can hold to our
higher standards, I think we are going to be in a better position.
Sorry for the editorial.
Dr Ahn. Thank you, George. I certainly agree with your
comments that we need to follow up our patients very carefully and
not just be technicians, and I think that is partly reflected in our
good results, because first of all we do have good follow-up on
these patients and good hemodynamic measurements, as well as
just eyeball measurements. I think that is partly why we have such
good secondary patencies, because we are able to intervene appro-
priately. I do measure intraoperative pressures for the iliacs rou-
tinely, but not for the SFA and tibials, because I don’t know how
to do that effectively, because when you put a catheter down into
an SFA and tibial and you are measuring the pressure distal to your
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what that pressure drop means past the catheter.
Dr Andros. Do you use the pressure wire?
Dr Ahn. That is a good suggestion. I had not used the
pressure wire. The cardiologists use that routinely, and it is also
very expensive, I might add. I’m not sure our hospital would look
favorably on that.
As far as characterization of the lesions, the tissue loss and
gangrene are obvious. I mean I don’t need to show you a picture of
that. Everyone in the room knows what gangrene and tissue loss is.
The ischemic rest pain is a little slippery slope, as you said, but these
were all patients—if they had ischemic rest pain, I think I know
after 20 years of practice, I think I know what ischemic rest pain is,
and I’ll now define that for the audience again. Patients with
dependent rubor and pallor on elevation who have dependent-
related ischemia worse at night and better when they hang their
foot over the edge associated with hemodynamic pressure mea-
surements or toe pressures, especially in diabetics, that corresponds
to the ischemic pain. I think my definition of ischemic rest pain is
pretty strict and very comparable to what most of the people in the
audience would use as well.
Dr Larry Kraiss (Salt Lake City, Utah). Nice paper, Sam, but I
think this is a paper that is begging for a comparisongroupor a control
group, and I would ask what you think the results would be if you
took your surgical patients and performed the same kind of analysis
that you have shown us with your interventional treated patients.
The second thing I would ask is, I share your opinion that
there is a difference between patients with tissue loss and rest pain,
tional PTA, subintimal angioplasty, newer technologies such asbut I would argue that the patient with rest pain actually needs a
more durable result perhaps than the patient with tissue loss, and
so I want to know if you approach those patients differently in
terms of your initial decision making.
Dr Ahn. That is a very good question, and I certainly agree
with you and thank you for that suggestion, because you are right.
We do not have a control group, and based on your suggestions, I
will go back and look at the 58 patients that we excluded, look at
them and compare to see how the open group did compared to
this. But nomatter what I do, this is a retrospective study, and what
you are really implying is that we need to do a good prospective
randomized trial. Now, Sam Wilson actually did that and reported
it back about 10 years ago in a VA population and showed that
there was no statistically significant difference between the open
bypass vs the endovascular PTA group in patients with infraingui-
nal lesions. For iliac lesions there was a slightly better improvement
in the open bypass, but it was only about a 10% difference.
Regarding your comments about the rest pain vs tissue loss,
the rest pain patients can often be treated by just improving one
level of occlusion. You don’t need to get a perfect–most of these
patients have multilevel disease. For tissue loss, you need to im-
prove at least two, maybe three, and get good flow down to the
foot, but for rest pain if you just take care of one level you will get
them out of that rest pain, so oftentimes in these patients if you just
take care of the inflow, say just the iliacs plus or minus the
profunda, you don’t need to do their SFA and tibials all the time to
get them out of the rest pain. For rest pain, you do not have to get
them perfect.INVITED COMMENTARYJoseph L. Mills, MD, Tucson, Ariz
The role of endoluminal therapy in the treatment of peripheral
arterial disease is dramatically expanding.1 Skeptics of endovascular
therapy oft opine that PTA [percutaneous transluminal angio-
plasty] works best for those least in need of intervention, thus
suggesting that PTA is reasonable for claudicants with focal lesions
but has little to offer patients with critical limb ischemia (CLI).
Ahn et al report a 10-year experience with a cohort of CLI patients
managed by endoluminal therapy. Over the study period, 111
patients (128 limbs; 63% of total) with CLI were treated by PTA
alone, whereas 76 limbs (37%) required open surgery. Technical
success was 96%, clinical success was 93%, 30-day mortality was
0.9%, and long-term limb salvage was 89%. At first glance, these
results in CLI patients after PTA are quite comparable to those of
open surgery and seem astonishing. However, the devil is in the
details.
The mean follow-up was short (14.7 months) and likely
reflected not only a shift toward less invasive approaches in recent
practice, but also the sobering reality that patients with CLI do not
live long (5-year series mortality of 56%). Many malignancies have
superior survival rates. In addition, 45% of patients had rest pain
without tissue loss, and 33% required only iliac PTA. It is no
surprise that PTA for hemodynamic iliac lesions often resolves
ischemic rest pain. Results were predictably worse in patients with
tissue loss and multiple, distal, or TransAtlantic Inter-Society
Consensus D lesions. Primary patency was low (31% at 5 years),
but secondary patency was 76%; this implies the necessity for
reintervention. The authors do not provide the frequency, mor-
bidity, or costs of repeat interventions. Primary patency, however,
may not be the ultimate objective of CLI treatment. A 5-year
clinical improvement rate (defined by Society of Vascular Surgery
category) of 80% and a 6-year limb salvage rate of 89% are more
meaningful end points.
What are the implications of this report? First, it is imperative
that vascular surgeons become facile with thrombolysis, conven-cutting balloons, and stent placement. These evolving therapies are
applicable to an increasing percentage of our patients. Second,
treatment outcomes require redefinition. Long-term patency
should not be the Holy Grail of outcome assessment, particularly
for CLI, in which symptom relief, lesion healing, and limb salvage,
withminimal morbidity, aremore critical end points. Open surgery
offers excellent patency rates, but morbidity is significant.2 Finally,
it is clear that as the proportion of peripheral arterial disease
patients effectively treated by endoluminal therapy expands, the
numbers of open cases for practicing vascular surgeons and resi-
dent trainees will continue to wane. A recent report identified the
difficulty in providing adequate numbers of open distal reconstruc-
tions for vascular surgical trainees because of the shift toward
subintimal angioplasty.3 New clinical training paradigms for resi-
dents and changes in the residency review committee case volume
and distribution (open vs PTA) requirements will need to be
rapidly implemented. Although there will be a role for tibial
bypasses and complex, open reconstructions for the foreseeable
future, “admit that the waters, around you have grown . . . for the
times they are a changin’.”4
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